Influenza Vaccine-Averted Illness in Chile, Guyana, and Paraguay During 2013–2018: A Standardized Approach to Assess the Value of Vaccination - Scorecard - MDSpire
Advertisement
Influenza Vaccine-Averted Illness in Chile, Guyana, and Paraguay During 2013–2018: A Standardized Approach to Assess the Value of Vaccination
Clinical Scorecard: Assessment of Influenza Vaccine Impact on Illness in Chile, Guyana, and Paraguay from 2013 to 2018: A Standardized Methodology for Evaluating Vaccination Benefits
At a Glance
Category
Detail
Condition
Seasonal influenza infection and associated respiratory illnesses
Key Mechanisms
Vaccination reduces influenza-associated respiratory disease events including symptomatic nonhospitalized illnesses, medically attended illnesses, and hospitalizations
Target Population
Young children (6–23 months or <5 years) and older adults (≥60 or ≥65 years) in Chile, Paraguay, and Guyana
Care Setting
Community and hospital settings in Latin American countries with and without influenza immunization programs
Key Highlights
Influenza vaccination averted tens of thousands of illnesses and thousands of hospitalizations in Chile and Paraguay between 2013 and 2018.
Vaccination coverage varied: 68% of children and 59% of older adults in Chile; 28% of children and 36% of older adults in Paraguay; no national program in Guyana.
A static compartmental model estimated vaccine-averted illnesses by comparing observed vaccination scenarios with hypothetical no-vaccination scenarios.
Guideline-Based Recommendations
Diagnosis
Use influenza surveillance data and hospitalization records to monitor influenza-associated respiratory disease burden.
Management
Implement influenza vaccination programs targeting WHO recommended groups: health workers, older adults, pregnant women, persons with comorbidities, and children aged 6–59 months.
Promote vaccination coverage to reduce influenza morbidity and hospitalizations.
Monitoring & Follow-up
Conduct vaccine effectiveness studies through networks such as PAHO SARInet plus and REVELAC-i.
Monitor vaccination coverage and influenza hospitalization rates to assess program impact.
Risks
Influenza infection causes significant morbidity and mortality globally and regionally, with substantial healthcare costs.
Low vaccination coverage may limit the potential benefits of vaccination programs.
Patient & Prescribing Data
Children aged 6–23 months or <5 years and older adults aged ≥60 or ≥65 years in Chile, Paraguay, and Guyana
Higher vaccination coverage correlates with greater reductions in influenza-associated illnesses and hospitalizations; absence of vaccination programs results in preventable disease burden.
Clinical Best Practices
Prioritize influenza vaccination in young children and older adults as per national guidelines.
Use surveillance and immunization registry data to inform and optimize vaccination strategies.
Communicate vaccine benefits to the public and healthcare providers to improve uptake.
Leverage standardized modeling approaches to estimate vaccine impact and support policy decisions.
by Jorge H Jara, Sergio Loayza, Francisco Nogareda, Paula Couto, Miguel Angel Descalzo, Anna N Chard, María Fernanda Olivares Barraza, Natalia Vergara Mallegas, Rodrigo A Fasce, Marta Von Horoch, Silvia Battaglia, Elena Penayo, Chavely Montserrat Dominguez, Cynthia Vazquez, Rainier Escalada, Janice Woolford, Fabiana Michel, Rafael Chacon, Ashley Fowlkes, Laura Castro, Martha Velandia-Gonzalez, Marc Rondy, Eduardo Azziz-Baumgartner, Stefano Tempia, Daniel Salas
Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.
Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.
